Myovant Sciences Ltd. (NYSE:MYOV) is expected to report second quarter earnings results, before market open, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.73 per share from revenue of $ 0.29 million.
Looking ahead, the full year loss are expected at $ 2.66 per share on the revenues of $ 38.80 million.
Previous Quarter Performance
Myovant Sciences Ltd. unveiled loss for the first quarter of $ 0.37 per share, from the revenue of $ 33.33 million. Street analysts expected Myovant Sciences Ltd. to report loss of $ 0.68 per share on revenue of $ 2.75 million for the first quarter.. The bottom line results beat street analysts by $ 0.31 or 45.59 percent.
Stock Performance
Shares of Myovant Sciences Ltd. traded up $ 0.89 or 5.67 percent on Wednesday, reaching $ 16.59 with volume of 868.00 thousand shares. Myovant Sciences Ltd. has traded high as $ 16.55 and has cracked $ 15.40 on the downward trend
The closing price of $ 16.59, representing a 176.41 % increase from the 52 week low of $ 5.68 and a 31.86 % decrease over the 52 week high of $ 23.04.
The company has a market capital of $ 1.50 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Myovant Sciences Ltd. will be hosting a conference call at 8:30 AM eastern time on 12th November 2020, to discuss its 2Q21 financial results with the investment community. The participants may dial, 1-800-532-3746 U.S. or +1-470-495-9166 (International) in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website myovant.com
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. The companys lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction.
